title: Urolithiasis in HIV-positive patients treated with atazanavir.
abstract: Among protease inhibitors, atazanavir has not been associated with urolithiasis in clinical studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human immunodeficiency virus (HIV) infection. Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization.
authors: Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Paul Brousse, Villejuif, France. couzigou@yahoo.fr
authors: Carine
authors: C
authors: Couzigou
authors: Michel
authors: M
authors: Daudon
authors: Jean Luc
authors: JL
authors: Meynard
authors: Françoise
authors: F
authors: Borsa-Lebas
authors: Denise
authors: D
authors: Higueret
authors: Lélia
authors: L
authors: Escaut
authors: David
authors: D
authors: Zucman
authors: Jean-Yves
authors: JY
authors: Liotier
authors: Jean-Louis
authors: JL
authors: Quencez
authors: Karine
authors: K
authors: Asselah
authors: Thierry
authors: T
authors: May
authors: Didier
authors: D
authors: Neau
authors: Daniel
authors: D
authors: Vittecoq
mesh_terms: D000328:Adult; D000069446:Atazanavir Sulfate; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D014556:Urine / Q000737:chemistry; D052878:Urolithiasis / Q000139:chemically induced*; D014867:Water / Q000378:metabolism
chemical_list: D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D014867:Water; D000069446:Atazanavir Sulfate